Startups
Spinogenix
Los Angeles, California, United States
Los Angeles clinical-stage biotechnology company founded by Stella Sarraf in 2016, developing small-molecule therapeutics intended to restore or correct brain synapses. Tazbentetol, formerly SPG302, is being investigated in ALS, Alzheimer’s disease and schizophrenia; SPG601, also named codabakalner, is being developed for Fragile X syndrome. The company’s research spans neurodegenerative, neuropsychiatric and neurodevelopmental conditions. Its candidates remain investigational: orphan designations, Fast Track status and an authorized expanded-access program are distinct from marketing approval. Public research support includes NIH and US Department of Defense grants, separate from equity financing. An SEC filing disclosed a fully sold USD5,199,985 equity offering in 2023; the March2026 filing describes an ongoing offering rather than a completed USD35 million financing.
Founded 2016
Team
 Craig EricksonChief Medical Advisor |
 Jerre SteadBoard Member |
 Joseph CoyleScientific Advisory Board Member |
 Justin IchidaScientific Advisory Board Member |
 Merit CudkowiczScientific Advisory Board Member |
 Mervyn TurnerBoard Member |
 Peter VanderklishChief Science Officer |
 Robert N. WeinrebScientific Advisory Board Member |
 Robert YoungScientific Advisory Board Member |
 Ryan MacDonaldChief Business Officer |
 Sasha Damouni EllisHead of Investor Relations |
 Sharron GargoskyChief Development Officer |
 Stella SarrafCEO, Founder, Director · Board Member |
 Steven ArnoldScientific Advisory Board Member |
 Steven YoungBoard Member |